The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study

Mentis Cura

Status: Completed

Conditions: AD

Treatments: Drug: Scopolamine

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02273895

MC-CT-001

Details and patient eligibility

About

The objective of this study is to compare the electroencephalography (EEG) responses of three distinct groups of individuals to scopolamine: 1) a group of Alzheimer Dementia (AD) patients, 2) a group of individuals suffering from Mild Cognitive Impairment (MCI) and 3) a group of controls. The main purpose of this comparison is to discover ways to use these responses to distinguish between the group of AD patients and controls in order to develop a diagnostic tool for AD. The purpose of including the MCI group is to investigate whether this diagnostic tool can predict which member of the MCI group will develop AD later in life.

Enrollment: 29 patients

Sex: All

Ages: 60 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Healthy subjects:

• Between 60-80 years of age.
• Volunteers will have to be in good general health as determined by standard physical examination.
• Normal Electrocardiograph (ECG)

MCI subjects:

• Diagnosed with MCI at the Memory Clinic at the Landspitali University Hospital using F 06,7 according to International Classification of Diseases (ICD) - 10.
• Between 60-80 years of age.
• Subjects need to score between 2 and 3 on the Global Deterioration Scale (GDS).
• Normal ECG

Alzheimer's patients:

• Diagnosed with AD according to ICD - 10 in Follow up at the Memory Clinic at the Landspitali University Hospital.
• Between 60-80 years of age.
• Subjects need to score between 3-5 on the GDS.
• Normal ECG
• Treated with Reminyl® for the Alzheimer disease.

Exclusion criteria

• Smoking or any other use of tobacco.
• Taking neuroleptics or benzodiazepines (allowed to take oxazepam ad vesp).
• Neurological-, cardiovascular-, gastrointestinal- or genitourinary disorders of medical importance.
• Glaucoma or history of possibly raised intraocular pressure.
• Impaired liver- or kidney function.
• Hypersensitivity to Scopolamine or any component in the formulation.
• Any indication of drug, alcohol or medicine abuse.
• Participation in another investigational study at the same time.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

29 participants in 3 patient groups

Control

Active Comparator group

Description:

Scopolamine

Treatment:

Drug: Scopolamine

MCI

Active Comparator group

Description:

Scopolamine

Treatment:

Drug: Scopolamine

AD

Active Comparator group

Description:

Scopolamine

Treatment:

Drug: Scopolamine